Xunfei Healthcare (2506 HK) Summary
Core Content and Key Highlights
Xunfei Healthcare, a leading player in China's medical AI market, reported FY25 revenue of RMB 915 million, representing a 24.7% YoY increase, slightly below estimates due to slower-than-expected growth in the G-end (government) segment in the second half of 2025. The B-end (business) segment, however, showed robust recovery, contributing to full-year growth of 31.1% YoY. The company's profitability improved significantly, with the attributable net loss narrowing by 51.1% YoY to RMB65 million, driven by enhanced operating leverage.
The company is executing a clear strategy to solidify its leadership in the G-end segment, accelerate B-end hospital penetration, and leverage GBC (Government, Business, Consumer) synergy to scale its C-end (consumer) patient services into a long-term growth engine. C-end revenue increased by 29% YoY to RMB273 million, accounting for approximately 30% of total revenue. This shift is significant as it moves the company from project-based government/hospital procurement toward a more recurring patient-paid business model.
Key Points
-
Market Expansion:
- Xunfei Healthcare expanded its client base in 2025, serving over 77,000 PHC (primary healthcare center) institutions across 806 districts and $600+$ graded hospitals.
- Continued provincial replication, such as full coverage of General Practice CDSS in Zhejiang and the first out-of-Anhui imaging cloud platform in Guangxi, indicates strong policy support for AI-assisted diagnosis.
-
C-end Business:
- The C-end segment is strategically important as it transitions the company toward a recurring revenue model.
- Early pilots of Digital and Intelligent Family Doctor in Shanghai and Shenzhen Longhua, along with AI-enabled post-discharge management at Qilu Hospital, suggest encouraging adoption.
- In 2025, the communication conversion rate for paying patients reached 50%, and NPS (Net Promoter Score) improved from 35% to 50%.
-
Financial Performance:
- Revenue growth slowed in 2H25 due to centralized provincial procurement compressing per-district project pricing.
- The company lowered its 2025–2028 revenue CAGR forecasts from 22.4% to 20.5% due to limited visibility on government procurement and project rollout.
- The target price was revised to HK$92.55, based on a 9x 2026E P/S (price-to-sales) multiple, reflecting broader sector de-rating.
Earnings Summary
| Metric |
FY24A |
FY25A |
FY26E |
FY27E |
FY28E |
| Revenue (RMB mn) |
734 |
915 |
1,119 |
1,347 |
1,599 |
| YoY growth (%) |
32.0 |
24.7 |
22.3 |
20.4 |
18.7 |
| Attributable net profit (RMB mn) |
(133) |
(65) |
(40) |
(21) |
3 |
| EPS (RMB cents) |
(1.16) |
(0.54) |
(0.33) |
(0.17) |
0.03 |
Stock Data
| Metric |
Value (HK$) |
| Market Cap |
8,413.1M |
| Avg 3 mths t/o |
33.2M |
| 52w High/Low |
133.40/66.60 |
| Total Issued Shares (mn) |
120.9 |
Shareholding Structure
| Shareholder |
Percentage |
| iFlytek |
49.4% |
| Hefei Zhengsheng |
16.1% |
Analyst Recommendations
- Maintain BUY
- Based on leadership in the China medical AI market.
- Target price: HK$92.55
- Previous target price: HK$143.59
- Up/Downside: 33.0%
- Current Price: HK$69.60
Peer Comparison
| Company |
Ticker |
Rating |
Price (LC) |
Market Cap (US$mn) |
Revenue (US$mn) |
| Tempus AI |
TEM US |
NA |
73.3 |
12,731 |
1,592 |
| Doximity Inc |
DOCS US |
NA |
64.4 |
12,055 |
643 |
| Veeva Systems |
VEEV US |
NA |
284.0 |
46,412 |
3,170 |
| Salesforce |
CRM US |
NA |
246.5 |
235,606 |
41,490 |
| Recursion Pharmaceuticals |
RXRX US |
NA |
4.8 |
2,071 |
85 |
Financial Summary
Income Statement
| Metric |
2023A |
2024A |
2025A |
2026E |
2027E |
2028E |
| Revenue |
556 |
734 |
915 |
1,119 |
1,347 |
1,599 |
| Gross profit |
315 |
404 |
462 |
572 |
693 |
828 |
| EPS (RMB) |
(1.16) |
(0.54) |
(0.33) |
(0.17) |
0.03 |
- |
Balance Sheet
| Metric |
2023A |
2024A |
2025A |
2026E |
2027E |
2028E |
| Total assets |
1,238 |
2,090 |
2,312 |
2,441 |
2,632 |
2,903 |
| Total liabilities |
688 |
1,103 |
1,365 |
1,450 |
1,579 |
1,764 |
| Total equity |
550 |
987 |
948 |
991 |
1,053 |
1,140 |
Cash Flow
| Metric |
2023A |
2024A |
2025A |
2026E |
2027E |
2028E |
| Net cash from operations |
(314) |
(134) |
73 |
109 |
69 |
104 |
| Net cash from investing |
0 |
(4) |
(578) |
(49) |
(49) |
(49) |
| Net cash from financing |
293 |
673 |
(11) |
40 |
(10) |
39 |
Growth and Profitability
| Metric |
2023A |
2024A |
2025A |
2026E |
2027E |
2028E |
| Revenue growth (%) |
17.9% |
32.0% |
24.7% |
22.3% |
20.4% |
18.7% |
| Gross profit margin |
56.6% |
55.1% |
50.5% |
51.1% |
51.4% |
51.8% |
| Net margin |
(10.2%) |
(6.1%) |
(1.2%) |
1.2% |
2.4% |
3.6% |
| ROE (%) |
(30.5%) |
(17.3%) |
(6.7%) |
(4.1%) |
(2.1%) |
0.3% |
Valuation Metrics
| Metric |
2023A |
2024A |
2025A |
2026E |
2027E |
2028E |
| P/S (x) |
13.6 |
10.3 |
8.3 |
6.8 |
5.6 |
4.7 |
| P/B (x) |
12.4 |
7.1 |
7.8 |
7.5 |
7.0 |
6.5 |
| P/E (x) |
ns |
ns |
ns |
ns |
ns |
2,210.7 |
Analyst Certification and Risk Disclaimer
- The analyst certifies that the views expressed in the report accurately reflect their personal views and that their compensation is not related to the report's content.
- The report is not an offer or solicitation to buy or sell any security.
- There are risks involved in transacting in any securities, and past performance does not guarantee future results.
- CMBIGM does not provide individually tailored investment advice and recommends that investors consult with a professional financial advisor.
